Saturn V Capital Management LP
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Saturn V Capital Management LP reported 25 stock positions worth $279.8 million. Its top holding was Ascendis Pharma A/S (ASND) at 10.7% of the portfolio, followed by Disc Medicine (IRON, 9.0%) and Vaxcyte (PCVX, 8.4%). Compared with Q2 2024, it opened 4 new positions, sold out of 5, added to 13 and reduced 8. The biggest buy was a new position in CG Oncology (CGON) and the biggest sale Argenx SE - ADR (ARGX, shares −66%).
- Most Recent 13F
- Q2 2026
- Location
- AUSTIN, TX
- CIK
- 0001964437
- Portfolio Value
- $279.8M (Q3 2024)
- SEC Filing
- 0001964437-24-000011 ↗ filed Nov 14, 2024
Holdings Value
Holdings 25 stocks · $279.8M
| ASND Ascendis Pharma A/S | 10.69% | 200,285 | $29.9M | Add +76.9% |
| IRON Disc Medicine Inc. | 8.98% | 511,041 | $25.1M | Add +1.6% |
| PCVX Vaxcyte Inc. | 8.37% | 204,987 | $23.4M | Reduce -5.0% |
| CGON CG Oncology Inc. | 7.01% | 520,119 | $19.6M | New |
| COGT Cogent Biosciences Inc. | 6.61% | 1,712,899 | $18.5M | Add +2.3% |
| CRGX Cargo Therapeutics Inc. | 6.61% | 1,002,461 | $18.5M | Add +17.0% |
| CYTK Cytokinetics Inc. | 6.25% | 331,283 | $17.5M | Add +21.8% |
| PHAT Phathom Pharmaceuticals Inc. | 5.65% | 874,590 | $15.8M | Add +47.4% |
| MLTX Moonlake Immunotherapeutics | 5.39% | 298,974 | $15.1M | New |
| CELC Celcuity Inc. | 5.04% | 946,335 | $14.1M | Add +24.4% |
| ARGX Argenx SE - ADR | 4.28% | 22,111 | $12.0M | Reduce -65.6% |
| SNDX Syndax Pharmaceuticals Inc. | 3.45% | 501,978 | $9.7M | Add +19.6% |
| SLN Silence Therapeutics PLC-ADR | 3.13% | 481,127 | $8.7M | New |
| ABVX Abivax SA-ADR | 2.67% | 648,019 | $7.5M | Add +3.2% |
| INZY Inozyme Pharma Inc. | 2.56% | 1,368,810 | $7.2M | Add +20.0% |
| MRUS Merus NV | 2.34% | 131,240 | $6.6M | Reduce -20.4% |
| KALV Kalvista Pharmaceuticals Inc. | 2.30% | 556,489 | $6.4M | Reduce -50.7% |
| NMRA Neumora Therapeutics Inc. | 2.04% | 432,996 | $5.7M | Add +11.0% |
| CRNX Crinetics Pharmaceuticals Inc. | 2.00% | 109,567 | $5.6M | Reduce -77.2% |
| IRWD Ironwood Pharmaceuticals Inc. | 1.65% | 1,120,409 | $4.6M | Add +0.6% |
| BMRN Biomarin Pharmaceutical Inc. | 0.94% | 37,432 | $2.6M | Reduce -79.0% |
| ITOS Iteos Therapeutics Inc. | 0.71% | 195,704 | $2.0M | Reduce -46.7% |
| CTNM Contineum Therapeutics Inc. Class A | 0.53% | 77,297 | $1.5M | Add +6.1% |
| AVBP Arrivent Biopharma Inc. | 0.40% | 47,266 | $1.1M | New |
| LBPH Longboard Pharmaceuticals Inc. | 0.38% | 31,529 | $1.1M | Reduce -55.9% |
Portfolio Sells Q2 2024 → Q3 2024
| ARGX Argenx SE - ADR | Reduce -65.6% | 4.28% | −6.15 |
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -77.2% | 2.00% | −6.12 |
| BMRN Biomarin Pharmaceutical Inc. | Reduce -79.0% | 0.94% | −4.62 |
| KALV Kalvista Pharmaceuticals Inc. | Reduce -50.7% | 2.30% | −2.72 |
| FOLD Amicus Therapeutics Inc. | Sold out | 0.00% | −2.67 |
| ANAB Anaptysbio Inc. | Sold out | 0.00% | −2.36 |
| ITOS Iteos Therapeutics Inc. | Reduce -46.7% | 0.71% | −1.35 |
| ELVN Enliven Therapeutics Inc. | Sold out | 0.00% | −1.34 |
| MRUS Merus NV | Reduce -20.4% | 2.34% | −1.34 |
| RAPP Rapport Therapeutics Inc. | Sold out | 0.00% | −0.62 |
| MORF Morphic Holding Inc. | Sold out | 0.00% | −0.61 |
| LBPH Longboard Pharmaceuticals Inc. | Reduce -55.9% | 0.38% | −0.35 |
| PCVX Vaxcyte Inc. | Reduce -5.0% | 8.37% | +2.22 |
Portfolio Buys Q2 2024 → Q3 2024
| CGON CG Oncology Inc. | New | 7.01% | +7.01 |
| MLTX Moonlake Immunotherapeutics | New | 5.39% | +5.39 |
| ASND Ascendis Pharma A/S | Add +76.9% | 10.69% | +4.85 |
| PHAT Phathom Pharmaceuticals Inc. | Add +47.4% | 5.65% | +3.34 |
| SLN Silence Therapeutics PLC-ADR | New | 3.13% | +3.13 |
| CRGX Cargo Therapeutics Inc. | Add +17.0% | 6.61% | +1.29 |
| COGT Cogent Biosciences Inc. | Add +2.3% | 6.61% | +1.28 |
| CYTK Cytokinetics Inc. | Add +21.8% | 6.25% | +0.68 |
| INZY Inozyme Pharma Inc. | Add +20.0% | 2.56% | +0.64 |
| NMRA Neumora Therapeutics Inc. | Add +11.0% | 2.04% | +0.60 |
| IRON Disc Medicine Inc. | Add +1.6% | 8.98% | +0.41 |
| AVBP Arrivent Biopharma Inc. | New | 0.40% | +0.40 |
| CELC Celcuity Inc. | Add +24.4% | 5.04% | +0.33 |
| SNDX Syndax Pharmaceuticals Inc. | Add +19.6% | 3.45% | +0.20 |
| CTNM Contineum Therapeutics Inc. Class A | Add +6.1% | 0.53% | +0.04 |
| ABVX Abivax SA-ADR | Add +3.2% | 2.67% | −0.47 |
| IRWD Ironwood Pharmaceuticals Inc. | Add +0.6% | 1.65% | −1.09 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $697.5M | AMLX, ALMS, ABVX, PCVX, IMMX |
| Q1 2026 | 21 | $552.2M | ALMS, AMLX, ABVX, PCVX, PHVS |
| Q4 2025 | 20 | $544.9M | ABVX, AMLX, COGT, JAZZ, PCVX |
| Q3 2025 | 17 | $456.0M | ABVX, AMLX, JAZZ, DYN, COGT |
| Q2 2025 | 24 | $246.8M | JAZZ, IRON, AMLX, PCVX, COGT |
| Q1 2025 | 21 | $198.2M | ASND, IRON, CGON, XENE, MRUS |
| Q4 2024 | 24 | $255.4M | IRON, ASND, MLTX, CGON, PCVX |
| Q3 2024 | 25 | $279.8M | ASND, IRON, PCVX, CGON, COGT |
| Q2 2024 | 26 | $264.6M | ARGX, IRON, CRNX, PCVX, ASND |
| Q1 2024 | 21 | $249.4M | CRNX, ARGX, CYTK, KALV, MRUS |